BTK and B-cell chronic lymphocytic leukemia: In CLL, studies of clonal evolution under treatment with the Bruton tyrosine kinase (BTK) inhibitor ibrutinib have provided novel insights into changes of the clonal architecture towards treatment resistance3,14.